Forum Topic News
  • Conversation: Lilly to progress Olumiant into PhIII for lupus

    • July 24, 2018 1:00 PM BST
      • Post(s)

      Lilly to progress Olumiant into PhIII for lupus

      The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
      According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.
      Also, compared to placebo, treatment with the drug resulted in a statistically significantly greater proportion of patients with lower overall disease activity, a key secondary endpoint.
      Based on these data, Lilly will initiate Phase III trials to evaluate the safety and efficacy of Olumiant for the treatment of SLE.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel